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In Norway in January 2008, unprecedented levels of os-
eltamivir resistance were found in 12 of 16 inﬂ  uenza viruses 
A (H1N1) tested. To investigate the epidemiologic and clinical 
characteristics of these viruses, we used sequence analysis 
to test all available subtype H1N1 viruses from the 2007–08 
season for resistance. Questionnaires from physicians pro-
vided information on predisposing diseases, oseltamivir use, 
symptoms, and complications. Clinical data were obtained 
for 265 patients. In total, 183 (67.3%) of 272 viruses were 
oseltamivir resistant. Resistance was not associated with 
prior use of antiviral drugs. Symptoms and hospitalization 
rates did not differ for patients infected with a resistant or 
a susceptible virus. Oseltamivir-resistant inﬂ  uenza viruses A 
(H1N1) did not show diminished capability to spread in the 
absence of selective pressure. The ability of these viruses to 
sustain their ﬁ  tness and spread among persons should be 
considered when shaping future strategies for treating and 
preventing seasonal and pandemic inﬂ  uenza.
S
easonal inﬂ   uenza, caused by inﬂ   uenza A subtypes 
H3N2 and H1N1 and inﬂ  uenza B viruses, occurs as 
annual epidemics. Although vaccination remains the pri-
mary measure for prevention, antiviral drugs are available 
for prevention and treatment of inﬂ  uenza. The inﬂ  uenza 
virus neuraminidase inhibitors zanamivir and oseltamivir 
were introduced into clinical practice in various parts of 
the world from 1999 through 2002 (1). Oseltamivir lim-
its replication of both inﬂ  uenza A and B viruses (1). In 
most European countries, neuraminidase inhibitors are not 
widely used to treat seasonal inﬂ  uenza, but they are being 
stockpiled in many countries as part of their pandemic in-
ﬂ  uenza preparedness. In Norway, oseltamivir is registered 
for prophylactic and therapeutic use in persons >1 year of 
age; however, it is not available without a prescription and 
it is rarely prescribed (2).
Until 2007, resistance against neuraminidase inhibi-
tors was rarely observed (1,3,4). Nevertheless, to better un-
derstand the potential for development of resistance against 
neuraminidase inhibitors, surveillance of antiviral suscep-
tibility in inﬂ  uenza virus in Europe has been ongoing since 
2004 (5). As part of the World Health Organization (WHO) 
Global Inﬂ  uenza Surveillance Network, the national in-
ﬂ  uenza centers in Europe submit inﬂ  uenza viruses to the 
WHO Inﬂ  uenza Collaborating Centre in the United King-
dom each inﬂ  uenza season. Within the framework of the 
European Surveillance Network for Vigilance against Viral 
Resistance (VIRGIL), these viruses are also tested for drug 
susceptibility at the Health Protection Agency in London.
In mid-January 2008, antiviral susceptibility testing 
(enzyme inhibition assays) of the ﬁ  rst shipment of inﬂ  u-
enza viruses from Norway for the 2007–08 season showed 
an unusually large proportion (5/7) of inﬂ  uenza viruses A 
(H1N1) with high-level resistance to oseltamivir. In sub-
sequent days, testing of additional viruses from Norway at 
the Norwegian national inﬂ  uenza center and at the Health 
Protection Agency conﬁ  rmed the high proportion of os-
eltamivir resistance. This unexpected and unprecedented 
discovery had possible public health implications of in-
ternational concern. On January 25, 2008, the Norwegian 
Institute of Public Health notiﬁ  ed WHO of these ﬁ  ndings 
under the International Health Regulations (6) and notiﬁ  ed 
the European Commission through the Early Warning and 
Response System. The Institute also informed hospitals and 
physicians in Norway about a possible lack of therapeutic 
effect when treating patients with oseltamivir. By the end 
of January, oseltamivir-resistant viruses had been reported 
from several European countries (7).
The oseltamivir-resistance trait is caused by a previous-
ly described point mutation in the virus neuraminidase gene 
(histidine to tyrosine at position 275 of the N1 neuramini-
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dase, commonly referred to as H274Y in N2 numbering), 
which is known to confer high-level resistance to oselta-
mivir while retaining susceptibility to zanamivir (8). Inﬂ  u-
enza viruses A (H1N1) carrying the H274Y mutation have 
reduced ability to replicate and transmit efﬁ  ciently when 
compared with parental, susceptible virus, but the clini-
cal implications of infection with these viruses have been 
largely unknown (9). Consequently, we undertook studies 
to determine whether the emergence and spread of the re-
sistant viruses were associated with exposure to oseltami-
vir, whether resistant viruses would continue to circulate in 
similar proportions into the epidemic phase of the season, 
and whether the new resistant viruses differed from their 
susceptible counterparts in their ability to cause disease. To 
do so, we tested all inﬂ  uenza viruses A (H1N1) available 
from the 2007–08 outbreak for oseltamivir susceptibility. 
We furthermore enhanced surveillance by collecting an ex-
tended set of data regarding clinical symptoms, complica-
tions, and prior exposure to oseltamivir for all laboratory-
veriﬁ  ed cases of inﬂ  uenza viruses A (H1N1) infection.
Methods
The inﬂ  uenza viruses A (H1N1) included in this study 
were obtained from the sentinel and nonsentinel collabora-
tors as part of routine national virologic inﬂ  uenza surveil-
lance. From all 19 counties, 71 sentinel practices collect 
samples from patients with inﬂ  uenza-like illness and send 
them to the national inﬂ  uenza center for diagnostic test-
ing. From all parts of the country, 15 medical microbiol-
ogy laboratories submit materials containing inﬂ  uenza A or 
B materials (original specimens, nucleic acid preparations 
from original specimens, or viral isolates) to the national 
inﬂ  uenza center for further characterization. Most of these 
samples originate from primary care clinics; the rest, from 
hospitals.
Viruses conﬁ  rmed as inﬂ  uenza A (H1), by either re-
verse transcription–PCR (RT-PCR) or virus isolation in 
MDCK cells and subsequent subtyping by immunoﬂ  uores-
cence, were included in the study. In-country susceptibility 
testing was performed by detecting the H274Y mutation by 
sequence analysis, through either a pyrosequencing assay 
targeting the single relevant point mutation (10) or through 
full- or partial-length cycle sequencing of the coding region 
for the viral neuraminidase. These analyses were mostly 
performed on RNA prepared from the original patient speci-
men. A large proportion of the isolated viruses were sent to 
the WHO Collaborative Centre for Inﬂ  uenza Research and 
Reference in the National Institute of Medical Research, 
Mill Hill, UK, for further characterization. Within the frame-
work of VIRGIL, these viruses were forwarded to the Health 
Protection Agency for phenotypic antiviral susceptibility 
testing and more extensive genotypic analyses. To determine 
neuraminidase susceptibility, assays to determine the drug 
concentration that provides 50% inhibition (IC50) were per-
formed by using the ﬂ  uorescent substrate methylumbellif-
eryl N-acetylneuraminic acid based on the method described 
by Wetherall et al. (11) with minor modiﬁ  cations.
Relative quantitative data on virus shedding, i.e., vi-
rus RNA content in the patient specimens, were obtained 
through a real-time RT-PCR targeting a conserved part 
of the matrix protein (M1) gene of inﬂ   uenza A virus. 
Two microliters of nucleic acid prepared from specimens 
(MagNApure LC Total Nucleic Acid Isolation Kit; Roche 
Diagnostics, Mannheim, Germany) was added to a 23-μL 
reaction mixture containing 0.3 μM forward primer M52c 
(5′-CTT CTA ACC GAG GTC GAA ACG-3′); 0.3 μM re-
verse primer M149r (5′-CTT GTC TTT AGC CAT TCC 
ATG AG-3′); 0.15 μM probe M93c (FAM-5′ CCG TCA 
GGC CCC CTC AAA GCC GA 3′-Black Hole Quencher 
1); and 5× QIAGEN OneStep RT-PCR buffer, dNTP mix-
ture, and enzyme mixture according to the manufacturer’s 
instructions (QIAGEN OneStep RT PCR Kit; QIAGEN, 
Hilden, Germany). Forward primer and probe sequences 
were as described by Fouchier et al. (12), and the reverse 
primer was designed by Tom Øystein Jonassen (Akershus 
University Hospital, Lørenskog, Norway). Reactions were 
run in a Corbett Rotorgene RG-3000 or RG-6000 thermocy-
cler (Corbett Research Pty Ltd, Sydney, New South Wales, 
Australia) with the following cycling conditions: reverse 
trancription for 30 min at 50°C, then 15 min at 95°C, fol-
lowed by 50 cycles at 95°C for 10 sec, 54°C for 30 sec, and 
72°C for 20 sec.
Participants and Study Design
We included all patients with a diagnosis of inﬂ  uenza 
virus A (H1N1) infection made by national inﬂ  uenza center 
during the 2007–08 inﬂ  uenza season. For the 72 patients 
who received this diagnosis before the end of January 
2008, data were collected retrospectively. From February 
on, data were collected as soon as possible after labora-
tory conﬁ  rmation of inﬂ  uenza virus A (H1N1) infection. 
Structured questionnaires returned from consulting physi-
cians provided auxiliary information about clinical signs 
and symptoms, complications, predisposing diseases for 
severe outcome of inﬂ   uenza (diabetes, cardiac disease, 
lung disease, and immunodeﬁ  ciency), use of oseltamivir, 
and inﬂ  uenza vaccination status. If the questionnaire was 
not returned by mail within 3 weeks, a reminder call was 
made. When available, relevant clinical information on the 
original referral sample form was used to supplement the 
data from the written questionnaire. The consulting physi-
cian, usually the primary care physician, was not informed 
about the result of the susceptibility testing when the infor-
mation was collected. Information for the ﬁ  rst 12 patients 
infected with a resistant virus was collected from the con-
sulting physicians by telephone.
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Statistical Analysis
Data from the questionnaires and selected laboratory 
testing outcomes were merged, checked for quality, and 
analyzed by using Stata version 9.0 (StataCorp LP, Col-
lege Station, TX, USA). We used the Fisher exact test to 
compare the proportions of possible confounders among 
those infected with a resistant and a susceptible virus. To 
estimate the association between exposure (resistant virus 
infection) and outcome (subsequent clinical ﬁ  ndings and 
complications), we calculated crude risk ratios (RRs) and 
95% conﬁ  dence intervals (CIs). We used binomial regres-
sion to calculate RRs adjusted for possible confounders. 
For each variable, we used the number of respondents as 
the denominator, except for predisposing disease, for which 
missing values were coded as “no.”
Results
The overall inﬂ  uenza activity in Norway was low in 
2007–08 compared with that of previous years. Virologic 
surveillance showed most inﬂ  uenza virus A and 95% of 
subtyped viruses to be subtype H1N1 (13). From the sen-
tinel practices, the national inﬂ  uenza center received 229 
specimens for inﬂ  uenza testing. Of the 108 that were posi-
tive for inﬂ  uenza virus, 61 were type A, subtype H1N1, 
and most of the rest were type B. In total, 297 patients 
had an inﬂ  uenza virus A (H1N1) infection conﬁ  rmed by 
the national inﬂ  uenza center in Norway from week 47 in 
2007 until the end of week 20 in 2008. We obtained a 
resistance proﬁ  le for 272 of the 297 viruses. We could 
not determine the resistance proﬁ  le for the remaining 25 
because of low virus content and consequently excluded 
them from analysis.
A total of 196 viral isolates were available (133 carried 
the resistance mutation); of these, 113 (79 with the resistant 
genotype) were reference tested by the VIRGIL laboratory. 
Phenotypic and genotypic reference analysis results agreed 
completely with the in-country genotypic testing results; all 
mutant viruses showed large reductions in susceptibility to 
oseltamivir when compared with non-H274Y viruses (IC50 
260–2,161 nM, mean 673 nM, for the 274Y mutant and 
0.4–5.6 nM, mean 2.6 nM, for the nonmutant viruses). No 
evidence of mixed genotype or phenotype was observed. 
In phylogenetic analysis of the H1 gene, all viruses tested 
grouped together in subclade 2B (Figure 1). In the phylo-
genetic tree, the resistant viruses from Norway all formed 
a single branch that was distinct, but closely related, to the 
susceptible viruses from Norway. 
Of the 272 inﬂ  uenza viruses A (H1N1), 183 (67.3%) 
were oseltamivir resistant (Table 1). The proportion of re-
sistant viruses did not differ between samples from sentinel 
67.9% (38/56) and nonsentinel 67.1% (145/216) practices 
and persisted throughout the season (Figure 2). No differ-
ence in virus shedding, as quantiﬁ  ed by real-time RT-PCR 
of available patient specimens, was observed between sus-
ceptible and resistant viruses (Figure 3). From the original 
sample form, we obtained demographic information for 
all 272 patients. Returned questionnaires provided infor-
mation for 265 patients (97.4%), but the response rate on 
individual questions varied. Of the 272 patients infected 
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Figure 1. Phylogenetic reconstruction of the H1 genes of inﬂ  uenza 
viruses A (H1N1) in Norway, 2007–08 season. The analysis was 
performed on an alignment spanning positions 84–1054 of viral RNA 
segment 4. Pairwise distances were calculated by using the Kimura 
2-parameter model with a transition:transversion ratio of 2.0; the 
phylogenetic tree was constructed by the neighbor-joining method, 
as implemented in the programs DNADIST and NEIGHBOR in the 
PHYLIP package (14,15). Published sequences were obtained 
from the Inﬂ   uenza Sequence Database, Los Alamos National 
Laboratory (16).  Boldface indicates viruses from the 2007–08 
inﬂ   uenza season in Norway; red indicates oseltamivir-resistant 
viruses; blue, susceptible viruses. New sequences presented in 
this analysis have been deposited in GenBank (accession nos. 
CY036664–CY036694).RESEARCH
with inﬂ  uenza viruses A (H1N1), 132 (48.5%) were male 
(Table 1), and slightly more than half (50.7%) were 29–64 
years of age (median 27 years, range 2 months–71 years); 
median ages of those infected with a resistant and a suscep-
tible virus were 31 and 21 years, respectively. The highest 
proportion of resistant virus infection was found for those 
25–59 years of age (102/138, 73.9%) and differed signiﬁ  -
cantly from the proportion for only those 5–14 years of age 
(25/45, 55.6%) (Fisher exact p = 0.03). We obtained inﬂ  u-
enza viruses A (H1N1) from 18/19 counties (Figure 4).The 
oseltamivir resistance proportion was >80% in 8 counties 
in southern Norway, compared with 63.5% in the rest of the 
country (Fisher exact p = 0.001).
Information about use of antiviral drugs was obtained 
for 237 patients. No patients had received antiviral treat-
ment in the 14 days before the onset of symptoms, and none 
had been in close contact with others known to have used 
antiviral drugs. Oseltamivir was received after sampling by 
7 patients, 5 of whom were infected with an oseltamivir-
resistant virus. Of 225 patients, 9 had traveled abroad in 
the week before symptom onset; 4 were infected with a 
resistant virus. Of all 272 patients, 2 had been vaccinated 
against inﬂ  uenza and were both infected with a resistant 
virus.
We received information about predisposing disease 
for 213 patients. Having a predisposing disease more 
than doubled the risk for complications (RR 2.5, 95% CI 
1.2–5.4) but was not clearly associated with being infected 
with a resistant virus (RR 1.4, 95% CI 0.6–3.2). Informa-
tion about clinical symptoms was obtained for 252/272 
patients; most frequently reported were fever (229/242) 
and dry cough (182/218). Resistant virus infection was not 
associated with any particular symptom (Table 2). Of 241 
patients, 58 (24.1%) had >1 complications recorded, but 
no difference was observed between those infected with 
a resistant virus and those infected with a susceptible vi-
rus (Table 2). Bronchitis and pneumonia were the most 
frequent complications, reported for 22 and 17 patients, 
respectively. The age of the 17 patients who had pneumo-
nia ranged from 8 months to 65 years (mean 29 years): 2 
(12.5%) were 0–4 years of age, 5 (31.3%) were 5–14 years 
of age, 2 (12.5%) were 15–24 years of age, 4 (25.0%) were 
25–59 years of age, and 3 (18.8%) were >59 years of age. 
Of the 17 patients with pneumonia, 15 were infected with a 
resistant virus. The attack rates of pneumonia and of sinus-
itis were higher for those infected with a resistant virus than 
for those infected with a susceptible virus, although the risk 
ratios were not statistically signiﬁ  cant after adjusting for 
age, gender, and predisposing disease (pneumonia RR 3.2, 
95% CI 0.7–13.7; sinusitis RR 1.7, 95% CI 0.4–7.5) (Table 
2). Of 264 patients, 45 had been hospitalized, 28 and 17 in-
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Table 1. Proportion of oseltamivir-resistant and oseltamivir-susceptible influenza viruses A (H1N1), 2007–08 influenza season, Norway
Sample source  Total no. samples  No. (%) resistant samples  No. (%) susceptible samples 
All 272 183 (67.3)  89 (32.7) 
Type of practice 
  Sentinel   56 38 (67.8)  18 (32.1) 
  Nonsentinel   216 145 (67.1)  71 (32.9) 
Patient gender 
  Male  132 85 (64.4)  47 (35.6) 
  Female  140 98 (70.0)  42 (30.0) 
Patient age group, y 
  0–4   45 27 (60.0)  18 (40.0) 
  5–14  45 25 (55.6)  20 (44.4) 
  15–24  31 20 (64.5)  11 (35.5) 
  25–59  138 102 (73.9)  36 (26.1) 
  60–99  13 9 (69.2)  4 (30.8) 
Patient with predisposing disease 
  Diabetes  10 9 (90.0)  1 (10.0) 
  Lung disease  11 8 (72.7)  3 (27.3) 
  Cardiac disease  5 2 (40.0)  3 (60.0) 
  Immunodeficiency  5 3 (60.0)  2 (40.0) 
  Any   27 20 (74.1)  7 (25.9) 
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Figure 2. Oseltamivir-resistant (n = 183) and oseltamivir-susceptible 
(n = 89) inﬂ  uenza viruses A (H1N1) in the 2007–08 inﬂ  uenza season 
in Norway, by week of sampling.Oseltamivir-Resistant Inﬂ  uenza Viruses A (H1N1) 
fected with a resistant and a susceptible virus, respectively. 
No deaths were reported for patients included in the study.
Discussion
During the 2007–08 inﬂ  uenza season in the Northern 
Hemisphere, widespread circulation of oseltamivir-resis-
tant inﬂ  uenza viruses A (H1N1) was observed. Percentage 
of resistant viruses circulating in different countries var-
ied markedly; the highest proportion reported worldwide 
(67%) was in Norway (17,18).
Our study did not show any association between os-
eltamivir use in Norway and emergence of the oseltami-
vir-resistant inﬂ  uenza viruses A (H1N1). Because only a 
minority of inﬂ  uenza cases are laboratory conﬁ  rmed, os-
eltamivir use in nonsampled persons could have contrib-
uted to the development of resistance. However, for this 
suggestion to be plausible, use of oseltamivir would have 
to be widespread to exert substantial selective pressure on 
the viruses. Sales of oseltamivir in Norway have been low: 
699 5-day regimens (0.15/1,000 population) were sold 
in 2004; 66,249 (14.4/1,000 population) in 2005; 33,573 
(7.3/1,000 population) in 2006; and 4,686 (1.0/1,000 pop-
ulation) in 2007 (2). In countries where oseltamivir use 
has been high, e.g., Japan, the proportion of oseltamivir-
resistant inﬂ  uenza viruses A (H1N1) reported during the 
2007–08 season was low (18). Because inﬂ  uenza strains 
from Norway were genetically similar to resistant viruses 
that appeared just as early in several other European coun-
tries (A. Hay, pers. comm.), we consider it unlikely that 
the resistant variant originated in Norway. Conceivably, 
the initial emergence of a resistant virus could be asso-
ciated with oseltamivir use elsewhere. Our data indicate 
that the viruses carrying this resistance mutation are fully 
capable of persistence and spread in the absence of selec-
tive pressure.
In Norway, the initially high proportion of resistant in-
ﬂ  uenza viruses A (H1N1) was maintained throughout the 
entire 2007–08 inﬂ  uenza season; countrywide, 2 of 3 viruses 
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Table 2. Reported associations for patients infected with oseltamivir-resistant or oseltamivir-susceptible influenza virus A (H1N1), 
2007–08 influenza season, Norway* 
Resistant, n = 183  Susceptible, n = 89 
Crude
associations
Adjusted
associations†
Association Attack rate, %  No. responses Attack rate, % No. responses  RR (95% CI)  RR (95% CI) 
Sign or symptom 
  Productive cough  38.4 125 31.9 47 1.2 (0.8–1.9) 
 Fever  94.4 162 95.0 80 1.0  (0.9–1.1) 
 Myalgia  72.9 129 73.3 60 1.0  (0.8–1.2) 
  Dry cough  82.1 145 86.3 73 1.0 (0.8–1.1) 
 Headache  63.4 131 67.2 58 0.9  (0.8–1.2) 
  Sore throat  57.5 134 67.2 58 0.9 (0.7–1.1) 
 Runny  nose  62.2 127 66.1 56 0.9  (0.8–1.2) 
Complication
  Pneumonia  9.2 153 2.9 69 3.2 (0.7–13.5)  3.2 (0.7–13.7) 
  Sinusitis  6.2 145 3.0 67 2.1 (0.5–9.4)  1.7 (0.4–7.5) 
  Otitis media  4.8 145 4.4 69 1.1 (0.3–4.2)  1.3 (0.4–4.8) 
  Bronchitis  8.7 149 11.8 76 0.7 (0.3–1.7)  0.8 (0.4–1.8) 
  Any   24.4 164 22.1 77 1.1 (0.7–1.8)  1.1 (0.7–1.8) 
Hospitalization 15.8 177 19.5 87 0.8 (0.5–1.4)  0.8 (0.5–1.3) 
*RR, risk ratio; CI, confidence interval. 
†RR adjusted for age, gender, and predisposing disease. 
Figure 3. Comparison of virus shedding, measured as relative viral 
RNA content, in respiratory specimens taken from patients infected 
with oseltamivir-susceptible and oseltamivir-resistant inﬂ  uenza 
viruses A (H1N1), respectively, during the 2007–08 inﬂ  uenza 
season in Norway. Viral RNA content is expressed as the reverse-
transcription–PCR cycle number (Ct) during which the ﬂ  uorescence 
threshold was exceeded.RESEARCH
were resistant. The reason for this exceptionally high resis-
tance proportion is unknown. However, it likely reﬂ  ects the 
proportion of resistant viruses introduced into Norway in 
the fall of 2007. Globally, the proportion of resistant inﬂ  u-
enza viruses A (H1N1) reported is highly variable between 
the different countries for which data are available (18). 
This large variation, apparently in the absence of oseltami-
vir selective pressure, suggests that a high level of random-
ness determined the frequency of resistance. In temperate 
countries, the inﬂ  uenza viruses are reintroduced each au-
tumn after the absence of inﬂ  uenza during the summer. If 
only a limited number of viruses are reintroduced into each 
country and initiate virus circulation and outbreaks, the 
result will be considerable random variation in virus vari-
ant proportions between the different countries. Consistent 
with this result, almost all the characterized inﬂ  uenza vi-
ruses A (H1N1) in Norway could be assembled into a small 
number of genetically discernible groups (Figure 1). We 
propose that such randomness in virus introductions may 
be sufﬁ  cient to explain the differences in the proportions of 
resistant viruses between the countries.
Conceivably, a difference in the antigenic characteris-
tics of the resistant and susceptible viruses could have fa-
vored one virus over the other in the face of host population 
immunity. Such differences might contribute to different 
relative effect of the 2 viruses in different populations (e.g., 
countries) or subpopulations (e.g., age groups). However, 
the resistant and susceptible viruses were closely related 
and were not distinguishable in hemagglutination inhibi-
tion tests (19).
Overall, the observed clinical manifestations associ-
ated with inﬂ  uenza viruses A (H1N1) in this study were as 
expected for seasonal inﬂ  uenza. No differences were noted 
for virus shedding, primary symptoms, or overall compli-
cation and hospitalization rates caused by oseltamivir-re-
sistant and -susceptible viruses. We did ﬁ  nd, although not 
a statistically signiﬁ  cant ﬁ  nding, that patients infected with 
a resistant virus appeared to be more likely than those in-
fected with a susceptible virus to have pneumonia or sinus-
itis. Patients with more severe illness may be more likely 
to be sampled; however, the resistance pattern of the virus 
was not known by the physician at the time of sampling 
and reporting. We therefore believe that these ﬁ  ndings are 
not inﬂ  uenced by selection bias. Adjusting for possible 
confounders (age, sex, and predisposing disease) did not 
change the results. Because of our limited sample size, the 
precision of our estimates is low, but they do indicate ﬁ  nd-
ings that warrant further investigation. Our data will also 
be analyzed with data from other European countries, and 
the ﬁ  ndings may strengthen the conclusions about the clini-
cal implications of oseltamivir-resistant inﬂ  uenza viruses 
A (H1N1) .
The future effect of resistant inﬂ   uenza viruses A 
(H1N1) is unpredictable. In Europe, the H1N1 subtype was 
predominant during the 2007–08 inﬂ  uenza season and, ac-
cording to historical patterns, is unlikely to predominate 
during the 2008–09 inﬂ   uenza season. In the following 
2008–09 season in the Northern Hemisphere, inﬂ  uenza vi-
ruses A (H1N1) may well predominate in areas where they 
had not recently been present in large numbers. Early re-
porting from the Southern Hemisphere 2008 inﬂ  uenza sea-
son indicates that detection of inﬂ  uenza virus A (H1N1) is 
low (20). However, in South Africa, oseltamivir resistance 
has been detected in 100% of inﬂ  uenza viruses A (H1N1) 
tested (21).
Whether oseltamivir-resistant viruses will persist be-
yond 2008 depends on several factors. First, their persis-
tence will depend on the prevalence of resistant viruses 
in the populations that are the source of global inﬂ  uenza 
spread. Countries in East and Southeast Asia have been 
proposed as the most likely source for global dissemina-
tion of new inﬂ  uenza virus variants (22). The prevalence 
of resistant inﬂ  uenza viruses A (H1N1) in this region may 
therefore be more likely to inﬂ  uence future occurrence of 
these viruses than the prevalence in Europe; resistance 
monitoring thus needs to be global. Second, changes in re-
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Figure 4. Proportion of oseltamivir-resistant inﬂ  uenza  viruses  A 
(H1N1) in the 2007–08 inﬂ  uenza season in Norway, by county of 
sampling. The total number of samples analyzed for each county is 
given inside each county.Oseltamivir-Resistant Inﬂ  uenza Viruses A (H1N1) 
cent inﬂ  uenza viruses A (H1N1) may have provided a ge-
netic background that permits H274Y mutants to replicate 
and transmit. Previous studies have concluded that resistant 
viruses are less pathogenic and less transmissible than their 
susceptible counterparts (9,23). In contrast, however, re-
verse genetics–derived mutants (A/WSN/33 or PR8 back-
bone) had the same phenotype as wild type viruses in vitro 
and in vivo (24,25). A recent study on the enzymatic prop-
erties of the N1 neuraminidase of the resistant viruses from 
the 2007–08 season suggested some genetic background 
changes that could potentially be involved (26).
As long as such a postulated permissive genetic back-
ground is common, resistant mutants may arise anew in 
purely oseltamivir-susceptible inﬂ  uenza virus A (H1N1) 
populations. Identiﬁ   cation of such predisposing genetic 
traits and monitoring of their occurrence in inﬂ  uenza virus-
es A (H1N1) and other inﬂ  uenza viruses should continue.
Similar resistance can arise in viruses other than the 
current human inﬂ  uenza viruses A (H1N1). Resistance in a 
more virulent inﬂ  uenza virus can have serious public health 
implications because of fewer therapeutic and prophylactic 
options, which may result in more persons being affected 
by inﬂ  uenza and more severe illness and death in those who 
become infected. Oseltamivir is a prime option for inﬂ  uen-
za treatment and prophylaxis and forms a substantial part of 
pandemic preparedness in many countries. The prevalence 
of oseltamivir-resistant viruses reported in Europe through-
out the 2007–08 inﬂ  uenza season clearly shows that this 
resistant mutation is stable and that these viruses sustain 
their ﬁ  tness and ability to spread among persons. These 
ﬁ  ndings should be taken into consideration when shaping 
future strategies for treating and preventing seasonal and 
pandemic inﬂ  uenza.
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